{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:14:30Z","timestamp":1792599270181,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013318","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000}}],"reference-count":73,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013318.pub2","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T13:18:02Z","timestamp":1686662282000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Fenofibrate for diabetic retinopathy"],"prefix":"10.1002","volume":"2023","author":[{"given":"Sachiko Y","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Health informatics; Kyoto University School of Public Health; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Lois","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumihiro","family":"Kawano","sequence":"additional","affiliation":[{"name":"Ophthalmology; Kurashiki Central hospital; Kurashiki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Kyoto Min-Iren Asukai Hospital; Kyoto Japan"},{"name":"Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine; Kyoto University; Kyoto Japan"},{"name":"Scientific Research Works Peer Support Group (SRWS-PSG); Osaka Japan"},{"name":"Department of Healthcare Epidemiology; Kyoto University Graduate School of Medicine \/ School of Public Health; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Inoue","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism; Ikeda City Hospital; Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Soseikai General Hospital; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013318.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013318.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD013318.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 12\u00a0","key":"10.1002\/14651858.CD013318.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.amjcard.2007.03.028","article-title":"Rationale, design, and methods of the action to control cardiovascular risk in diabetes eye study (ACCORD-EYE)","volume":"99","author":"Chew","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD013318.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2443-51","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"issue":"Suppl 1A","key":"10.1002\/14651858.CD013318.pub2-BIB0006|cit6","first-page":"A178","article-title":"Effect of fenofibrate on cardiovascular events and mortality in women with type 2 diabetes: results from the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"58","author":"D'Emden","year":"2009","journal-title":"Diabetes"},{"issue":"9","key":"10.1002\/14651858.CD013318.pub2-BIB0007|cit7","first-page":"1","article-title":"The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"3","author":"FIELD Study Investigators","year":"2004","journal-title":"Cardiovascular Diabetology"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0008|cit8","unstructured":"Fenofibrate intervention and event lowering in diabetes www.isrctn.com\/ISRCTN64783481? 10.1186\/ISRCTN64783481"},{"issue":"9500","key":"10.1002\/14651858.CD013318.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet\u00a0"},{"issue":"9600","key":"10.1002\/14651858.CD013318.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1687-97","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1002\/14651858.CD013318.pub2-BIB0011|cit11","first-page":"1","article-title":"Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate","volume":"4","author":"Scott","year":"2005","journal-title":"Cardiovascular Diabetology"},{"issue":"7","key":"10.1002\/14651858.CD013318.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2337\/dc16-0024","article-title":"Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the action to control cardiovascular risk in diabetes (ACCORD) follow-on study","volume":"39","author":"Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0013|cit13","unstructured":"A randomised multi-centre placebo controlled trial of fenofibrate for treatment of diabetic macular oedema with economic evaluation (FORTE Study) anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12618000592246"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00125-021-05532-1","article-title":"Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial","volume":"64","author":"Bonora","year":"2021","journal-title":"Diabetologia"},{"issue":"10","key":"10.1002\/14651858.CD013318.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"JC5","DOI":"10.7326\/0003-4819-153-10-201011160-02010","article-title":"Intensifying glucose control and adding fenofibrate to simvastatin each reduced progression of retinopathy in type 2 diabetes","volume":"153","author":"Bronson","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013318.pub2-BIB0016|cit16","first-page":"2155","article-title":"Efficacy of fenofibrate combined with 23G minimally invasive vitrectomy for diabetic retinopathy","volume":"18","author":"Cui","year":"2018","journal-title":"International Eye Science"},{"issue":"1","key":"10.1002\/14651858.CD013318.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clinical Lipidology"},{"issue":"3","key":"10.1002\/14651858.CD013318.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10557-008-6160-5","article-title":"More clinical lessons from the FIELD study","volume":"23","author":"Fazio","year":"2009","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"6","key":"10.1002\/14651858.CD013318.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"330-3","DOI":"10.1177\/14746514050050060601","article-title":"Fenofibrate in type 2 diabetes: the FIELD study","volume":"5","author":"Feher","year":"2005","journal-title":"British Journal of Diabetes and Vascular Disease"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0020|cit20","unstructured":"Fenofibrate reduces laser treatment needs in patients with diabetic retinopathy Australian Journal of Pharmacy 2008 89 1061 77"},{"issue":"13","key":"10.1002\/14651858.CD013318.pub2-BIB0021|cit21","first-page":"22","article-title":"Fenofibrate reduces the need for laser treatment for diabetic retinopathy","volume":"150","author":"Fuessl","year":"2008","journal-title":"MMW-Fortschritte der Medizin"},{"issue":"3","key":"10.1002\/14651858.CD013318.pub2-BIB0022|cit22","first-page":"344","article-title":"Fenofibrate effect on diabetic retinopathy","volume":"21","author":"Grigoryeva","year":"2011","journal-title":"European Journal of Ophthalmology."},{"issue":"5","key":"10.1002\/14651858.CD013318.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"307-17","DOI":"10.3109\/09286586.2014.949783","article-title":"Effects of fenofibric acid on diabetic macular edema: the MacuFen study","volume":"21","author":"Massin","year":"2014","journal-title":"Ophthalmic Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013318.pub2-BIB0024|cit24","first-page":"518","article-title":"Effects of fenofibric acid on diabetic macular edema measured by optical coherence tomography","volume":"22","author":"Massin","year":"2012","journal-title":"European Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD013318.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"45-6","DOI":"10.1136\/ebm1155","article-title":"Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study","volume":"16","author":"Matthews","year":"2011","journal-title":"Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0026|cit26","unstructured":"Effect of lipid lowering agents on diabetic retinopathy and cardiovascular risk of diabetic patients clinicaltrials.gov\/ct2\/show\/study\/NCT04140201"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0027|cit27","unstructured":"Effects of oral fenofibrate on retinal thickness and macular volume clinicaltrials.gov\/ct2\/show\/NCT04885153"},{"issue":"1","key":"10.1002\/14651858.CD013318.pub2-BIB0028|cit28","first-page":"17-26","article-title":"Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE","volume":"2","author":"O'Connor","year":"2011","journal-title":"Therapeutic Advances in Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013318.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"98-105","DOI":"10.4103\/ijo.IJO_566_17","article-title":"Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema","volume":"66","author":"Srinivasan","year":"2018","journal-title":"Indian Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD013318.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"A442","DOI":"10.1016\/j.jval.2013.08.684","article-title":"Evaluating the cost-utility of fenofibrate treatment of diabetic retinopathy in Australia","volume":"16","author":"Valentine","year":"2013","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0031|cit31","unstructured":"The fenofibrate and microvascular event eye (FAME 1 EYE) trial in adults with type 1 diabetes mellitus: a randomised trial in adults with type 1 diabetes mellitus evaluating the effects of daily oral fenofibrate compared with placebo on macular thickness and volume anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12611000249954"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0032|cit32","unstructured":"The fenofibrate and microvascular events in type 1 diabetes eye (FAME 1 EYE) clinicaltrials.gov\/ct2\/show\/NCT01320345"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0033|cit33","unstructured":"Lowering events in non-proliferative retinopathy in Scotland clinicaltrials.gov\/ct2\/show\/nct03439345"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013318.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13063-017-1902-y","article-title":"LENS-a clinical trial embedded in routine clinical practice to reduce the burden of diabetic eye disease","volume":"18\u00a0","author":"Preiss","year":"2017","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0035|cit35","unstructured":"Fenofibrate for prevention of DR worsening (protocol AF) clinicaltrials.gov\/ct2\/show\/NCT04661358"},{"issue":"5","key":"10.1002\/14651858.CD013318.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ophtha.2009.10.002","article-title":"Factors associated with improvement and worsening of visual acuity 2 years after focal\/grid photocoagulation for diabetic macular edema","volume":"117","author":"Aiello","year":"2010","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013318.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000174541","article-title":"Review of European clinical experience with fenofibrate","volume":"76","author":"Blane G","year":"1989","journal-title":"Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD013318.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD013318.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"686525","DOI":"10.1155\/2013\/686525","article-title":"Molecular implications of the PPARs in the diabetic eye","volume":"2013","author":"Ciudin","year":"2013","journal-title":"PPAR Research"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0041|cit41","unstructured":"Covidence Veritas Health Innovation"},{"issue":"11","key":"10.1002\/14651858.CD013318.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/14656566.2016.1195811","article-title":"Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review","volume":"17","author":"Czupryniak","year":"2016","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0043|cit43","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) on behalf of the Cochrane Statistical Methods Group Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022), Cochrane, 2022 Available at www.training.cochrane.org\/handbook"},{"issue":"14","key":"10.1002\/14651858.CD013318.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"pii: 93751","DOI":"10.1172\/jci.insight.93751","article-title":"Diabetic retinopathy: current understanding, mechanisms, and treatment strategies","volume":"2","author":"Duh","year":"2017","journal-title":"JCI Insight"},{"issue":"4","key":"10.1002\/14651858.CD013318.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/aos.14377","article-title":"Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review","volume":"98","author":"Elkjaer","year":"2020","journal-title":"Acta Ophthalmologica"},{"issue":"Suppl 5\u00a0","key":"10.1002\/14651858.CD013318.pub2-BIB0046|cit46","first-page":"823","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD013318.pub2-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011234.pub2","article-title":"Laser photocoagulation for proliferative diabetic retinopathy","author":"Evans","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013318.pub2-BIB0048|cit48","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ebiom.2016.09.025","article-title":"Fenofibrate inhibits cytochrome P450 epoxygenase 2C activity to suppress pathological ocular angiogenesis","volume":"13","author":"Gong","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0050|cit50","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"20","key":"10.1002\/14651858.CD013318.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD013318.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1345\/aph.18432","article-title":"Micronized fenofibrate: a new fibric acid hypolipidemic agent","volume":"33","author":"Guay","year":"1999","journal-title":"Annals of Pharmacotherapy"},{"issue":"12","key":"10.1002\/14651858.CD013318.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD013318.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-010-1836-3","article-title":"Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden","volume":"53","author":"Heintz","year":"2010","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0055|cit55","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"38","key":"10.1002\/14651858.CD013318.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1073\/pnas.1307211110","article-title":"Pathogenic role of diabetes-induced PPAR-alpha down-regulation in microvascular dysfunction","volume":"110","author":"Hu","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Liu Q Zhang F Zhang X Cheng R Ma JX Yi J Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation Molecular and Cellular Biochemistry 2018 445 1-2 105 15","DOI":"10.1007\/s11010-017-3256-x"},{"issue":"7","key":"10.1002\/14651858.CD013318.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1001\/jamaophthalmol.2021.0606","article-title":"Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial","volume":"139","author":"Maturi","year":"2021","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0059|cit59","unstructured":"McCulloch DK Nathan DM Trobe J Mulder JE Diabetic retinopathy: pathogenesis www.uptodate.com\/contents\/diabetic-retinopathy-pathogenesis"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0060|cit60","unstructured":"Review Manager \u00a0(RevMan) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0061|cit61","unstructured":"Review Manager Web (Rev Man Web) The Cochrane Collaboration 2023"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12886-016-0318-x","article-title":"Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up","volume":"16","author":"Romero-Aroca","year":"2016","journal-title":"BMC Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD013318.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/IAE.0b013e3181884f2d","article-title":"Medicare expenditures associated with diabetes and diabetic retinopathy","volume":"29","author":"Schmier","year":"2009","journal-title":"Retina"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0064|cit64","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions V ersion 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"10085","key":"10.1002\/14651858.CD013318.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","article-title":"The progress in understanding and treatment of diabetic retinopathy","volume":"51","author":"Stitt","year":"2016","journal-title":"Progress in Retinal and Eye Research"},{"issue":"14","key":"10.1002\/14651858.CD013318.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e14999","DOI":"10.1097\/MD.0000000000014999","article-title":"Efficacy of fenofibrate for diabetic retinopathy: a systematic review protocol","volume":"98","author":"Su","year":"2019","journal-title":"Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013318.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","article-title":"Diabetic macular oedema","volume":"5","author":"Tan","year":"2017","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"11","key":"10.1002\/14651858.CD013318.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD013318.pub2-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub6","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","author":"Virgili","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013318.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1472-6963-10-136","article-title":"Healthcare costs associated with progressive diabetic retinopathy among National Health Insurance enrollees in Taiwan, 2000-2004","volume":"10","author":"Woung","year":"2010","journal-title":"BMC Health Service Research"},{"issue":"7","key":"10.1002\/14651858.CD013318.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"e0180949","DOI":"10.1371\/journal.pone.0180949","article-title":"Direct medical cost associated with diabetic retinopathy severity in type 2 diabetes in Singapore","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1002\/14651858.CD013318.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013318","article-title":"Fenofibrate for diabetic retinopathy","author":"Inoue","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T14:47:29Z","timestamp":1735915649000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013318.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":73,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013318.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}